References
- Holland J F. Kamofsky memorial lecture. breaking the cure barrier. J Clin Oncol 1983; 1: 74–90
- Zekan P J, Muss HB., Capizzi R L. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin and cyclophosphamide in advanced carcinoma of the breast: A phase II study of the Piedmont Oncology Association. Cancer 1984; 54: 2338–2343
- Jones R B, Holland J F, Bhardwai S. A phase I—II study of intensive dose adriamycin for advanced breast cancer. J Clin Oncol 1987; 5: 172–177
- Durzu R, Takuma N, Wanner W L. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer 1987; 56: 874–883
- Lippman M E. Efforts to combine endocrine and Chemotherapy in the management of breast cancer. Breast Cancer Res Treat 1983; 3: 117–127
- Paterson A HS, Szafran O, Hanson J. Response to treatment and its influence on survival in metastatic breast cancer. Am J Clin Oncol 1985; 8: 283–292
- Goldie J H. Drug resistance and cancer chemotherapy strategy in breast cancer. Breast Cancer Res Treat 1983; 3: 129–136
- Frei E, Canellos G P. Dose a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
- Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 11: 1281–1288
- Hoogstraten B. Adriamycin in the treatment of advanced breast cancer: Studies by the Southwest Oncology Group. Cancer Chem-other Rep 1975; 6: 329–339
- Tormey D C. Adriamycin in breast cancer. An overview of studies. Cancer Chemother Rep 1975; 6: 319–327
- Hoogastraten B, Fabian C. A reappraisal of single drug in advanced breast cancer. Cancer Clin Trials 1979; 2: 101–109
- Razak E, Valeriote F, Vietti T. Survival of hemopoietic and leukemia colony-forming cells in vitro following the administration of daunorubicin or adriamycin. Cancer Res 1972; 32: 1496–1500
- Lefrak E A, Pitha J, Rosenhein S, Gottlieb J A. A clinicopath-ologic analysis of adriamycin cardiotoxicity. Cancer 1973; 39: 1397–1402
- Von Hoff D D, Layard M W, Basa P. Risk factors for doxorubicin induced congestive breast failure. Ann Intern Med 1979; 91: 710–717
- Casazza A M. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979; 63: 835–844
- Bonfante V, Villani F, Bonadonna G. Toxic and therapeutic activity of 4′-epidoxorubicin. Tumori 1982; 68: 105–111
- Schauer P K, Wittes R E, Gralla R J. A phase I trial of 4′-Epi-Adriamycin. Cancer Clin Trials 1981; 4: 433–437
- Ganzina F. 4′-Epidoxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983; 10: 1–22
- Neri B, Bartalucci S, Cinelli P. Clinical aspects of doxorubicin and epirubicin cardiotoxicity in cancerous patients. Cum Ther Res 1988; 43: 609–618
- Karnofsky D A, Burchenal J H. The clinical evaluation of chem-otherapeutic agents. Evaluation of Chemotherapeutic Agents, McLeod. Columbia University Press., New York 1949; 191–205
- Alexander J, Dainiak N, Berger H J. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278–283
- Miller A B, Hoogstraten B, Staquet M, Wikler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
- Kaplan E L, Meyer P. Non parametric estimation from incompletc observations. J Am Stat Assoc 1958; 53: 457–4381
- Macauly V, Smith I E. Advanced breast cancer. Randomized Trials in Cancer, a Critical Review by Sites, ML Slevin, MJ Staquet. Raven Press, New York 1986; 273–358
- Steiner R, Stewart J F, Cantwell B JM. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1983; 19: 1553–1561
- Henderson I C. Chemotherapy for advanced disease. Breast Disease, JR Harris, S Hellman, IC Henderson, DW Kinn. Lippincott, Philadelphia 1987; 428–479
- Nagel G A. High-dose Epirubicin in combination with cyclophosphamide in advanced breast cancer: A phase II study. Proc ECCO 5. London 1989; 9–12